---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-044353"
form_type: "8-K"
ticker: "ANTX"
cik: "0001880438"
company_name: "AN2 Therapeutics, Inc."
filed_at: "2025-03-25T23:59:59+00:00"
generated_at: "2026-05-24T06:07:43.692161+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AN2 Therapeutics reports FY2024 net loss $51.3M; Phase 3 epetraborole data expected 2Q25

## Summary
- Cash, equivalents, investments $88.6M at Dec 31, 2024; expected to fund operations through 2027.
- FY2024 net loss $51.3M vs $64.7M prior year; Q4 net loss $7.5M vs $16.9M.
- Phase 3 topline data for epetraborole in treatment-refractory MAC lung disease due 2Q25.
- Phase 1 trial of AN2-502998 for Chagas disease to start mid-2025 in healthy volunteers.
- First oncology candidate from boron chemistry platform on track to advance in 2H25.

## SEC filing metadata
- accession: 0000950170-25-044353
- form_type: 8-K
- ticker: ANTX
- cik: 0001880438
- company_name: AN2 Therapeutics, Inc.
- filed_at: 2025-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1880438/000095017025044353/0000950170-25-044353-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1880438/000095017025044353/antx-20250325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-044353
- JSON: https://secwatch.observer/filing/0000950170-25-044353.json
- Plain text: https://secwatch.observer/filing/0000950170-25-044353.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.